Background: New randomized, controlled trials have become available on oral P2Y12
inhibitors in acute coronary syndrome. We aimed to evaluate current evidence comparing …

Background Prior reports indicate that the effect of P2Y12 inhibitors may be different in East
Asian patients (“East Asian paradox”); therefore, understanding the outcomes associated …

Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …

Aims Non-ST-elevation acute coronary syndrome (NSTE-ACS) is present in about 60–70%
of patients admitted with acute coronary syndromes in clinical practice. This study provides a …

Newer oral P2Y 12 inhibitors are more potent and have faster onset of action than
clopidogrel. However, the efficacy and safety in patients with non–ST-elevation acute …

Background: No randomized head-to-head comparison of the efficacy and safety of
ticagrelor and prasugrel has been published in the 7 years since the higher efficacy of these …

Background: Few data on the relative efficacy and safety of new P2Y 12 inhibitors such as
prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute …

Dual antiplatelet therapy with aspirin and the oral P2Y12 inhibitor clopidogrel as the
cornerstone of treatment for patients with an acute coronary syndrome (ACS) undergoing …

BACKGROUND: Antiplatelet therapy is essential treatment for acute coronary syndromes
(ACS). Current therapies, however, have important limitations affecting their clinical success …

Prasugrel is a new P2Y 12 receptor antagonist that has been investigated for the treatment
of atherothrombosis in patients with cardiovascular disease undergoing percutaneous …